Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 116 | NANETS2025 | Next issue

NANETS 2025

18th Annual Multidisciplinary NET Medical Symposium NANETS 2025

Clinical – Chemo/SSA/Biologics

Previous section
Applied Basic Science
Table of contents
Next section
Clinical – Nuclear Medicine/Interventional Radiology/Imaging

ea0116c1 | Clinical – Chemo/SSA/Biologics

An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression

ea0116c2 | Clinical – Chemo/SSA/Biologics

Prognostic Significance of MEN1, ATRX, and DAXX Mutations in Pancreatic Neuroendocrine Tumors Treated with CAPTEM: Insights from a Multicenter Cohort

ea0116c3 | Clinical – Chemo/SSA/Biologics

Investigator-Assessed Disease Progression in a Phase 2 Study of Paltusotine in Patients with Neuroendocrine Tumors and Carcinoid Syndrome

ea0116c4 | Clinical – Chemo/SSA/Biologics

Multicenter Real-World Study of Treatment Patterns in Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

ea0116c5 | Clinical – Chemo/SSA/Biologics

PPM1D as a Potential Driver of Myeloid Malignancy Transformation in Neuroendocrine Tumor (NET) Pts: An Underrecognized Malignant CHIPerpetrator?

ea0116c6 | Clinical – Chemo/SSA/Biologics

TROP2 Expression in the Gastroenteropancreatic Neuroendocrine Tumors; An analysis of 179 patients

ea0116c7 | Clinical – Chemo/SSA/Biologics

The Hidden Cost of Enzyme Therapy: Oxalate Nephropathy in a NET Patient with Pancreatic Insufficiency

ea0116c8 | Clinical – Chemo/SSA/Biologics

DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

ea0116c9 | Clinical – Chemo/SSA/Biologics

Somatic genomic profiling of gastrointestinal neuroendocrine tumors: Implications for prognostication and therapeutic targeting

ea0116c10 | Clinical – Chemo/SSA/Biologics

The Efficacy of Low-dose vs Standard-dose Everolimus in Patients with Advanced Neuroendocrine Tumors

ea0116c11 | Clinical – Chemo/SSA/Biologics

The useful combination of capecitabine and temozolomide (CAPTEM) in metastatic lung carcinoid tumors

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2026 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more